About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 133  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2022  |  Volume : 15  |  Issue : 1  |  Page : 81-84

Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia

1 Chevron Eye Hospital and Research Centre, Chittagong, Bangladesh
2 Orbit, Oculoplasty and Oncology Clinic, Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh

Correspondence Address:
Dr. Murtuza Nuruddin
Chevron Eye Hospital and Research Centre, Chittagong
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ojo.ojo_146_21

Rights and Permissions

Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded48    
    Comments [Add]    

Recommend this journal